Coinfection with SARS-CoV-2 and Cytomegalovirus in a Patient with Mild COVID-19

Table 1

Laboratory examinations on admission.

Complete blood count
WBC	8000	μL
Neutrophils	29.0	%
Lymphocytes	57.0	%
Monocytes	11.0	%
Eosinophils	3.0	%
Basophils	—	%
Atypical lymphocytes	—	%
Ht	44.5	%
RBC	548	×10^4/μl
Hb	15.9	g/dL
Plt	19.8	×10^4/μl
Biochemical examinations
TP	7.1	g/dL
Alb	3.6	g/dL
BUN	10.1	mg/dL
Crea	0.59	mg/dL
T-Bil	0.9	mg/dL
AST	40	U/L
ALT	68	U/L
γGTP	40	U/L
ALP	108	U/L
LDH	281	U/L
CK	26	U/L
CRP	7.81	mg/dL
PCT	0.19	ng/mL
Glu	322	mg/dL
HbA1c	10.9	%
Immunology and infection
IgM	95	mg/dL
IgG	1329	mg/dL
IgA	429	mg/dL
C3	178	mg/dL
C4	46	mg/dL
CH50	61.2	mL
HBs-Ag	0.01	IU/mL
HCV-Ab	0.02	C.O.I
EBV-VCA IgM (FAT)	<10.0
EBV-EBNA (FAT)	40
HSV IgM (EIA)	0.25
HIV Ag/Ab (CLEIA)	(−)
CD4	764	/μL
CD4/CD8	0.35

WBC, white cell count; Ht, hematocrit; RBC, red cell count; Hb, hemoglobin; Plt, platelet count; PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; APTT, activated partial thromboplastin time; FDP, fibrin/fibrinogen degradation products; TP, total protein; Alb, albumin; BUN, blood urea nitrogen; Cre, creatinine; T-Bil, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGTP, gamma-glutamyl transpeptidase: ALP, alkaline phosphatase; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, C-reactive protein; PCT, procalcitonin; Glu, glucose; HbA1c, hemoglobin A1c; IgM, immunoglobulin M; IgG, immunoglobulin G; IgA, immunoglobulin A; HBs-Ag, hepatitis B surface antigens; HCV-Ab, hepatitis C antibody; EBV, Epstein–Barr virus; VCA, viral capsid antigen; FAT, fluorescent antibody technique; EBNA, Epstein–Barr virus nuclear antigen; HSV, herpes simplex virus; EIA, enzyme immunoassay; HIV, human immunodeficiency virus; Ag/Ab, antigen/antibody; and CLEIA, chemiluminescent enzyme immunoassay.